Update Breast Cancer 2020 Part 1 - Early Breast Cancer: Consolidation of Knowledge About Known Therapies.
digital medicine
early breast cancer
immune therapy
prevention
prognosis
therapy
Journal
Geburtshilfe und Frauenheilkunde
ISSN: 0016-5751
Titre abrégé: Geburtshilfe Frauenheilkd
Pays: Germany
ID NLM: 0370732
Informations de publication
Date de publication:
Mar 2020
Mar 2020
Historique:
received:
27
01
2020
revised:
03
02
2020
accepted:
03
02
2020
entrez:
7
3
2020
pubmed:
7
3
2020
medline:
7
3
2020
Statut:
ppublish
Résumé
This review is intended to present the latest developments in the prevention and treatment of early breast cancer. The risk of breast cancer can be increasingly better characterised with large epidemiological studies on genetic and non-genetic risk factors. Through new analyses, the evidence for high-penetrance genes as well as for low-penetrance genes was able to be improved. New data on denosumab and atezolizumab are available in the neoadjuvant situation as is a pooled appraisal of numerous studies on capecitabine in the curative situation. There is also an update to the overall survival data of pertuzumab in the adjuvant situation with a longer follow-up observation period. Finally, digital medicine is steadily finding its way into science. A recently conducted study on automated breast cancer detection using artificial intelligence establishes the basis for a future review in clinical studies.
Identifiants
pubmed: 32139917
doi: 10.1055/a-1111-2431
pii: 11112431
pmc: PMC7056401
doi:
Types de publication
Journal Article
Langues
eng
Pagination
277-287Déclaration de conflit d'intérêts
Conflict of Interest/Interessenkonflikt A. D. H. received speaker and consultancy honoraria from AstraZeneca, Genomic Health, Roche, Novartis, Celgene, Lilly, MSD, Eisai, Teva, Tesaro, Daiichi Sankyo, Hexal and Pfizer. F. O. received speaker and consultancy honoraria from Amgen, AstraZeneca, Bayer, BMS, Boehringer-Ingelheim, Chugai, Celgene, Cellex, Eisai, Gilead, Hexal, Ipsen, Janssen-Cilag, Merck, MSD, Novartis, Novo Nordisk, Riemser, Roche, Servier, Shire, Tesaro, Teva. H.-C.K . received honoraria from Carl Zeiss meditec, Teva, Theraclion, Novartis, Amgen, AstraZeneca, Pfizer, Janssen-Cilag, GSK, LIV Pharma, Roche, Genomic Health, Theramex, ClinSol and onkowissen.de, travel support from Carl Zeiss meditec, Novartis, Amgen, AstraZeneca, Pfizer LIV Pharma, Genomic Health, Tesaro and Daiichi Sankyo and owns stock from Theraclion and Phaon Scientific. P. A. F. received honoraria from Novartis, Pfizer, Roche, Amgen, Celgene, Daiichi Sankyo, AstraZeneca, Merck-Sharp & Dohme, Eisai, Puma and Teva. His institution conducts research with funding from Novartis and Biontech. H. T. received honoraria from Novartis, Roche, Celgene, Teva, Pfizer and travel support from Roche, Celgene and Pfizer. J. E. received honoraria from AstraZeneca, Roche, Celgene, Novartis, Lilly, Pfizer, Pierre Fabre, Teva and travel support from Celgene, Pfizer, Teva and Pierre Fabre. M. P. L. has participated on advisory boards for AstraZeneca, Lilly, MSD, Novartis, Pfizer, Eisai, Genomic Health and Roche and has received honoraria for lectures and medical education activities from MSD, Lilly, Roche, Novartis, Pfizer, Genomic Health, AstraZeneca, medac, onkowissen.de, ClinSol and Eisai. V. M. received speaker honoraria from Amgen, AstraZeneca, Celgene, Daiichi Sankyo, Eisai, Pfizer, Novartis, Roche, Teva, Janssen-Cilag and consultancy honoraria from Genomic Health, Hexal, Roche, Pierre Fabre, Amgen, Novartis, MSD, Daiichi Sankyo and Eisai, Lilly, Tesaro and Nektar. E. B. received honoraria from Novartis, Hexal and onkowissen.de for consulting, clinical research management or medical education activities. A. S. received honoraria from Roche, Celgene, AstraZeneca, Novartis, Pfizer, Zuckschwerdt Verlag GmbH, Georg Thieme Verlag, Aurikamed GmbH, MCI Deutschland GmbH, bsh medical communications GmbH and promedicis GmbH. W. J. received honoraria and research grants from Novartis, Roche, Pfizer, Lilly, AstraZeneca, Chugai, Sanofi, Daichi, Tesaro. F. S. participated on advisory boards for Novartis, Lilly, Amgen and Roche and received honoraria for lectures from Roche, AstraZeneca, MSD, Novartis and Pfizer. A. W. participated on advisory boards for Novartis, Lilly, Amgen, Pfizer, Roche, Tesaro, Eisai, Celgene, Teva, Hexal, AstraZeneca, Sirtex, MSD and received honoraria for lectures from Novartis, Pfizer, Aurikamed, Roche, Amgen, Eisai, Lilly, AstraZeneca, Genomic Health, ClinSol, onkowissen.de. D. L. received honoraria from Amgen, AstraZeneca, Celgene, ClinSol, Lilly, Loreal, MSD, Novartis, onkowissen.de, Pfizer, Tesaro, Teva T. N. F. has participated on advisory boards for Amgen, Daiichi Sankyo, Novartis, Pfizer, and Roche and has received honoraria for lectures from Amgen, Celgene, Daiichi Sankyo, Roche, Novartis and Pfizer. M.T . has participated on advisory boards for AstraZeneca, Lilly, MSD, Novartis, Pfizer, Genomic Health and Roche and has received honoraria for lectures from MSD, Lilly, Roche, Novartis, Pfizer, Genomic Health, and AstraZeneca. M. W. has participated on advisory boards for AstraZeneca, Lilly, MSD, Novartis, Pfizer and Roche. J. H. reports receiving speakers bureau honoraria from Celgene, Novartis, and Roche, and is a consultant/advisory board member for Amgen, Celgene, Novartis and Roche./ A. D. H. hat Referenten- und Beraterhonorare von AstraZeneca, Genomic Health, Roche, Novartis, Celgene, Lilly, MSD, Eisai, Teva, Tesaro, Daiichi Sankyo, Hexal und Pfizer erhalten. F. O. hat Referenten- und Beraterhonorare von Amgen, AstraZeneca, Bayer, BMS, Boehringer-Ingelheim, Chugai, Celgene, Cellex, Eisai, Gilead, Hexal, Ipsen, Janssen-Cilag, Merck, MSD, Novartis, Novo Nordisk, Riemser, Roche, Servier, Shire, Tesaro und Teva erhalten. H.-C.K . hat Honorare von Carl Zeiss meditec, Teva, Theraclion, Novartis, Amgen, AstraZeneca, Pfizer, Janssen-Cilag, GSK, LIV Pharma, Roche, Genomic Health, Theramex, ClinSol und onkowissen.de sowie Reiseförderungen von Carl Zeiss meditec, Novartis, Amgen, AstraZeneca, Pfizer LIV Pharma, Genomic Health, Tesaro und Daiichi Sankyo erhalten und hält Aktien von Theraclion und Phaon Scientific. P. A. F. hat Honorare von Novartis, Pfizer, Roche, Amgen, Celgene, Daiichi Sankyo, AstraZeneca, Merck-Sharp & Dohme, Eisai, Puma und Teva erhalten. Die Forschungsaktivitäten seiner Einrichtung werden finanziell von Novartis and Biontech unterstützt. H. T. hat Honorare von Novartis, Roche, Celgene, Teva und Pfizer sowie Reiseförderungen von Roche, Celgene und Pfizer erhalten. J. E. hat Honorare von AstraZeneca, Roche, Celgene, Novartis, Lilly, Pfizer, Pierre Fabre und Teva sowie Reiseförderungen von Celgene, Pfizer, Teva und Pierre Fabre erhalten. M. P. L. war Mitglied von Beratungsgremien für AstraZeneca, Lilly, MSD, Novartis, Pfizer, Eisai, Genomic Health und Roche und hat Honorare für Vorträge sowie medizinische Schulungen von MSD, Lilly, Roche, Novartis, Pfizer, Genomic Health, AstraZeneca, medac, onkowissen.de, ClinSol und Eisai erhalten. V. M. hat Referentenhonorare von Amgen, AstraZeneca, Celgene, Daiichi Sankyo, Eisai, Pfizer, Novartis, Roche, Teva und Janssen-Cilag sowie Beraterhonorare von Genomic Health, Hexal, Roche, Pierre Fabre, Amgen, Novartis, MSD, Daiichi Sankyo and Eisai, Lilly, Tesaro und Nektar erhalten. E. B. hat Honorare von Novartis, Hexal und onkowissen.de für Beratungstätigkeiten, die Leitung klinischer Forschungsvorhaben bzw. medizinische Schulungen erhalten. A. S. hat Honorare von Roche, Celgene, AstraZeneca, Novartis, Pfizer, Zuckschwerdt Verlag GmbH, Georg Thieme Verlag, Aurikamed GmbH, MCI Deutschland GmbH, bsh medical communications GmbH und promedicis GmbH erhalten. W. J. hat Honorare und Forschungsstipendien von Novartis, Roche, Pfizer, Lilly, AstraZeneca, Chugai, Sanofi, Daichi und Tesaro erhalten. F. S. war Mitglied von Beratungsgremien für Novartis, Lilly, Amgen und Roche und hat Vortragshonorare von Roche, AstraZeneca, MSD, Novartis und Pfizer erhalten. A. W. war Mitglied von Beratungsgremien für Novartis, Lilly, Amgen, Pfizer, Roche, Tesaro, Eisai, Celgene, Teva, Hexal, AstraZeneca, Sirtex und MSD und hat Vortragshonorare von Novartis, Pfizer, Aurikamed, Roche, Amgen, Eisai, Lilly, AstraZeneca, Genomic Health, ClinSol und onkowissen.de erhalten. D. L. hat Honorare von Amgen, AstraZeneca, Celgene, ClinSol, Lilly, Loreal, MSD, Novartis, onkowissen.de, Pfizer, Tesaro und Teva erhalten. T. N. F. war Mitglied von Beratungsgremien für Amgen, Daiichi Sankyo, Novartis, Pfizer und Roche und hat Vortragshonorare von Amgen, Celgene, Daiichi Sankyo, Roche, Novartis und Pfizer erhalten. M.T . war Mitglied von Beratungsgremien für AstraZeneca, Lilly, MSD, Novartis, Pfizer, Genomic Health und Roche und hat Vortragshonorare von MSD, Lilly, Roche, Novartis, Pfizer, Genomic Health und AstraZeneca erhalten. M. W. war Mitglied von Beratungsgremien für AstraZeneca, Lilly, MSD, Novartis, Pfizer und Roche. J. H. gibt an, Referentenvermittlungshonorare von Celgene, Novartis und Roche zu erhalten und ist Berater/Mitglied von Beratungsgremien für Amgen, Celgene, Novartis und Roche.
Références
Nat Genet. 2013 Apr;45(4):392-8, 398e1-2
pubmed: 23535733
Geburtshilfe Frauenheilkd. 2019 May;79(5):470-482
pubmed: 31148847
Nat Genet. 2015 Apr;47(4):373-80
pubmed: 25751625
JAMA Oncol. 2017 Sep 1;3(9):1190-1196
pubmed: 28418444
BMC Cancer. 2011 Nov 14;11:486
pubmed: 22081974
N Engl J Med. 2017 Jul 13;377(2):122-131
pubmed: 28581356
Nat Genet. 2015 Nov;47(11):1294-1303
pubmed: 26414677
Nat Genet. 2012 Jan 22;44(3):312-8
pubmed: 22267197
N Engl J Med. 2018 Aug 23;379(8):753-763
pubmed: 30110579
Ann Oncol. 2019 Aug 1;30(8):1232-1243
pubmed: 31056702
Am J Hum Genet. 2016 Oct 6;99(4):903-911
pubmed: 27640304
Nat Genet. 2010 Oct;42(10):885-92
pubmed: 20852631
N Engl J Med. 2018 Nov 29;379(22):2108-2121
pubmed: 30345906
JAMA Oncol. 2017 Oct 1;3(10):1378-1385
pubmed: 28715532
Nat Genet. 2017 Dec;49(12):1767-1778
pubmed: 29058716
Breast Cancer Res. 2015 Aug 16;17:110
pubmed: 26275715
Lancet. 2016 Jan 16;387(10015):229-38
pubmed: 26494415
Ann Surg Oncol. 2015 May;22(5):1441-6
pubmed: 25727556
Ann Oncol. 2018 Dec 1;29(12):2341-2347
pubmed: 30335131
Cancer Epidemiol Biomarkers Prev. 2012 Jul;21(7):1156-66
pubmed: 22454379
Nat Genet. 2013 Apr;45(4):353-61, 361e1-2
pubmed: 23535729
Nat Genet. 2020 Jan;52(1):56-73
pubmed: 31911677
J Natl Cancer Inst. 2018 Aug 1;110(8):855-862
pubmed: 30099541
J Natl Cancer Inst. 2015 Apr 08;107(5):
pubmed: 25855707
Nat Genet. 2018 Jul;50(7):968-978
pubmed: 29915430
Nat Genet. 2013 Apr;45(4):371-84, 384e1-2
pubmed: 23535731
J Clin Oncol. 2012 May 20;30(15):1796-804
pubmed: 22508812
Cancer Res. 2012 Apr 1;72(7):1795-803
pubmed: 22331459
Breast Cancer Res Treat. 2018 Aug;171(1):85-94
pubmed: 29725888
PLoS One. 2020 Jan 30;15(1):e0228446
pubmed: 31999755
J Clin Oncol. 2019 Sep 1;37(25):2226-2234
pubmed: 31082269
Am J Hum Genet. 2019 Jan 3;104(1):21-34
pubmed: 30554720
Breast Cancer Res. 2019 May 22;21(1):68
pubmed: 31118087
Lancet Oncol. 2016 Mar;17(3):345-356
pubmed: 26869049
Nature. 2020 Jan;577(7788):89-94
pubmed: 31894144
Breast Care (Basel). 2019 Aug;14(4):247-255
pubmed: 31558898
J Natl Cancer Inst. 2015 Mar 04;107(5):
pubmed: 25745020
Nat Commun. 2016 Apr 27;7:11375
pubmed: 27117709
Nat Genet. 2017 Jun;49(6):834-841
pubmed: 28436984
J Clin Oncol. 2018 Aug 1;36(22):2281-2287
pubmed: 29791287
Nat Genet. 2011 Oct 30;43(12):1210-4
pubmed: 22037553
Lancet Oncol. 2013 Dec;14(13):1269-77
pubmed: 24225155
N Engl J Med. 2019 Feb 14;380(7):617-628
pubmed: 30516102
Lancet Oncol. 2019 Mar;20(3):339-351
pubmed: 30795951
Nat Genet. 2013 Apr;45(4):362-70, 370e1-2
pubmed: 23535730
Nature. 2020 Jan;577(7788):35-36
pubmed: 31894156
Lancet. 2014 Feb 15;383(9917):603-13
pubmed: 24224997
Breast Care (Basel). 2019 Aug;14(4):224-245
pubmed: 31558897
Clin Cancer Res. 2019 May 1;25(9):2717-2724
pubmed: 30563931
Geburtshilfe Frauenheilkd. 2019 Oct;79(10):1079-1089
pubmed: 31656318
N Engl J Med. 2017 Aug 10;377(6):523-533
pubmed: 28578601
Carcinogenesis. 2014 May;35(5):1012-9
pubmed: 24325915
Geburtshilfe Frauenheilkd. 2018 May;78(5):481-492
pubmed: 29880983
N Engl J Med. 2005 Oct 20;353(16):1659-72
pubmed: 16236737
Ann Oncol. 2019 Apr 1;30(4):558-566
pubmed: 30689707
Geburtshilfe Frauenheilkd. 2019 Oct;79(10):1090-1099
pubmed: 31656319
Nature. 2017 Nov 2;551(7678):92-94
pubmed: 29059683
N Engl J Med. 2005 Oct 20;353(16):1673-84
pubmed: 16236738
N Engl J Med. 2011 Oct 6;365(14):1273-83
pubmed: 21991949
Pract Radiat Oncol. 2017 Mar - Apr;7(2):73-79
pubmed: 27866865